Roche Holding Dirección

Dirección controles de criterios 3/4

El CEO de Roche Holding's es Thomas Schinecker , nombrado en Mar 2023, tiene una permanencia de 1.08 años. compensación anual total es CHF5.34M, compuesta por 23.4% salario y 76.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0% de las acciones de la empresa, por valor de CHF636.93K. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 7.1 años, respectivamente.

Información clave

Thomas Schinecker

Chief Executive Officer (CEO)

CHF5.3m

Compensación total

Porcentaje del salario del CEO	23.4%
Permanencia del CEO	1.1yrs
Participación del CEO	0.0003%
Permanencia media de la dirección	4.5yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thomas Schinecker en comparación con los beneficios de Roche Holding?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	CHF11b
Sep 30 2023	n/a	n/a	CHF11b
Jun 30 2023	n/a	n/a	CHF11b
Mar 31 2023	n/a	n/a	CHF12b
Dec 31 2022	CHF5m	CHF1m	CHF12b
Sep 30 2022	n/a	n/a	CHF14b
Jun 30 2022	n/a	n/a	CHF15b
Mar 31 2022	n/a	n/a	CHF14b
Dec 31 2021	CHF4m	CHF1m	CHF14b
Sep 30 2021	n/a	n/a	CHF14b
Jun 30 2021	n/a	n/a	CHF14b
Mar 31 2021	n/a	n/a	CHF14b
Dec 31 2020	CHF4m	CHF879k	CHF14b
Sep 30 2020	n/a	n/a	CHF14b
Jun 30 2020	n/a	n/a	CHF13b
Mar 31 2020	n/a	n/a	CHF13b
Dec 31 2019	CHF2m	CHF609k	CHF13b

Compensación vs. Mercado: La compensación total ($USD5.85M) de Thomas está en línea con el promedio de empresas de tamaño similar en el mercado Swiss ($USD6.42M).

Compensación vs. Ingresos: La compensación de Thomas ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Thomas Schinecker (48 yo)

1.1yrs

Permanencia

CHF5,335,592

Compensación

Dr. Thomas Schinecker serves as Chairman of the Board at Genentech, Inc. since March 2023. He serves as Chief Executive Officer at Roche Holding AG since March 15, 2023. He has been Chief Executive Officer...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Severin Schwan	Executive Chairman	11.1yrs	CHF11.48m	0.039% CHF 68.8m
Thomas Schinecker	Chief Executive Officer	1.1yrs	CHF5.34m	0.00035% CHF 623.8k
Alan Hippe	Chief Financial & Information Officer	13yrs	CHF6.05m	0.0059% CHF 10.6m
Bruno Eschli	Head of Investor Relations	no data	sin datos	sin datos
Claudia Bockstiegel	General Counsel	4yrs	sin datos	sin datos
Pascale Schmidt	Chief Compliance Officer	4.3yrs	sin datos	sin datos
Barbara Schadler	Head of Group Communications	4.5yrs	sin datos	sin datos
Cristina Wilbur	Chief People Officer	8.1yrs	CHF4.25m	0.0018% CHF 3.3m
Nicolas Dunant	Head of Group Media Relations	no data	sin datos	sin datos
Boris Zaitra	Head of Group Business Development and M&A	no data	sin datos	sin datos
James H. Sabry	Global Head of Pharma Partnering	5.7yrs	sin datos	sin datos
Paulo Fontoura	Head of Neuroscience Clinical Development	no data	sin datos	sin datos

4.5yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ROG se considera experimentado (4.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Severin Schwan	Executive Chairman	11.1yrs	CHF11.48m	0.039% CHF 68.8m
Bernard Poussot	Non-Executive Independent Director	9.3yrs	CHF330.00k	0.00013% CHF 231.7k
Ulf Schneider	Director	1.1yrs	sin datos	sin datos
Andre Hoffmann	Independent Vice Chairman	28.3yrs	CHF402.82k	3.53% CHF 6.3b
Patrick Frost	Independent Non Executive Director	4.1yrs	CHF360.00k	0.00025% CHF 445.5k
Richard Lifton	Non-Executive Independent Director	9.3yrs	CHF346.71k	0% CHF 0
Anita Hauser	Non-Executive Independent Director	7.1yrs	CHF336.16k	0.00040% CHF 712.9k
Jorg Duschmale	Non-Executive Independent Director	4.1yrs	CHF364.59k	sin datos
Akiko Iwasaki	Director	1.1yrs	sin datos	sin datos
Claudia Ricarda Rita Suessmuth Dyckerhoff	Non-Executive Independent Director	8.1yrs	CHF367.02k	0.00034% CHF 605.9k
Jemilah Mahmood	Independent Non-Executive Director	2.1yrs	CHF272.50k	sin datos

7.1yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de ROG se considera experimentada (7.1 años de antigüedad promedio).

Roche Holding Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche Holding AG Announces Executive Appointments

Recent updates

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

European Commission Approves Roche Holding AG's Fixed-Term Columvi (Glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell L-Cell Lymphoma

Roche Receives FDA Clearance for Additional Alzheimer's Disease Cerebrospinal Fluid Assays, Supporting Timely Diagnosis and Treatment Decision-Making

Roche Looking to Sell or Shut Down Vacaville, California Plant

Does Roche Holding (VTX:ROG) Have A Healthy Balance Sheet?

Roche Announces U.S. Food and Drug Administration Accepted Supplemental Biologics License Application for Vabysmo

Upcoming dividend of CHF9.50 per share at 3.6% yield

Roche Announces Positive New Data from Two Global phase III studies, BALATON and COMINO

Full year 2022 earnings: EPS misses analyst expectations

Roche Announces Positive Data from Global Phase III Programme for Crovalimab in PNH, A Rare Life-Threatening Blood Condition

Roche Holding AG Announces Executive Appointments

Roche Launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-Variant

Roche Announces the Phase III IMbrave050 Study Met Its Primary Endpoint of Recurrence-Free Survival (RFS) At the Prespecified Interim Analysis

Roche Announces the European Commission Approval of Xofluza for the Treatment and Prevention of Influenza in Children Aged One Year and Above

FDA approves Roche Holding AG’s Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphoma

Roche Presents New Data Demonstrating the Potential Benefit of Glofitamab and Lunsumio as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta